Express Scripts unveils 2016 formulary

Pharmacy benefit manager Express Scripts Holding Co. (NASDAQ:ESRX) released a list of 73 therapies it will not cover in 2016.

Diabetes drugs Onglyza saxagliptin and Kombiglyze XR from AstraZeneca plc (LSE:AZN; NYSE:AZN) were moved to the excluded list in 2016 from preferred status in 2015. Onglyza is a dipeptidyl peptidase-4 ( DPP-4; CD26) inhibitor and Kombiglyze XR is a fixed-dose combination of once-daily saxagliptin and extended-release metformin. ...